TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01521546

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eplerenone
Description: 25mg tablet, once daily by mouth for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet by mouth daily for 12 months
Study: NCT03875404

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: A special type of MRI measuring the metabolic changes that occur within the brain. It may be used to examine the brain's anatomy and determine which parts of the brain are handling critical functions. It helps identify important language and movement control areas in the brain.
Study: NCT01685944

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Pediococcus pentosaceus LP28

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Heat-killed Pediococcus pentosaceus LP28

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01205204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
Study: NCT01024075

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
Study: NCT04591470

Intervention type: DIAGNOSTIC_TEST
Intervention: Mar test
Description: Study of antisperm antibodies

Intervention type: DIAGNOSTIC_TEST
Intervention: Mar test
Description: Study of antisperm antibodies
Study: NCT00506077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0249
Description: MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo (unspecified)
Description: MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
Study: NCT02275689

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic acromioplasty
Description: Surgical intervention With arthroscopic acromion resection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microtenotomy
Description: Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
Study: NCT01234012

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMF-001
Description: subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
Study: NCT02831075

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose-derived stem cell
Description: stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study: NCT04645459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low phosphorus meals
Description: All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control meals
Description: All subjects followed their usual diets but took one tablet of calcium carbonate as phosphate binder per meal for the first week washout diet. After washout diet, subjects were assign to control or study group randomly and entered to the study period for one week. The diets of the study group were low phosphorus ( LP group), but the dietary phosphorous levels of the control group were not modified. During the study period, all subjects including LP group and control group still kept their usually accustomed behavior about regular breakfast and also took one tablet of calcium carbonate as phosphate binder with every breakfast meal. The LP group and control group replaced daily lunch and dinner with low phosphorus and standard meals respectively and should not take any phosphate binder during the study period for one week.
Study: NCT03698669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treating Opioid Patients' Pain and Sadness (TOPPS)
Description: TOPPS involves an initial face-to-face meeting followed by regular phone meetings. In preliminary research, patients found this format to be convenient. The initial meeting includes the patient, the BHS and the PCP; the PCP then regularly receives treatment notes from the BHS. Also, the PCP, who has a longitudinal relationship with the patient, is encouraged to further reinforce TOPPS goals. After each TOPPS session, the BHS also mails a copy of the clinical note to the patient. Additionally, each participant is provided with a workbook that reviews the key elements of each treatment session and provides exercises for at-home practice of skills.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Description: After an initial, brief, joint, in-person meeting with the BHS and primary care physician (PCP), patients have a session that discusses nutrition. For the next 5 telephone sessions, they choose from a menu of topics, including: a second session on nutrition; germs, colds and the flu; preventing cancer; diabetes; protecting your heart; getting a good night's sleep; complementary and alternative medicine; caffeine, or physical activity. This control condition was accepted by our participants in preliminary studies; it does not directly target functional impairment, and participants do not set tailored goals relating to their own values. The BHS will communicate with the PCP only if a participant shows signs of clinical deterioration.
Study: NCT01024075

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 8cc of Saline mixed with Sinufoam
Study: NCT01556334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Azithromycin 1g po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Erythromycin IV then PO
Study: NCT04439253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO
Study: NCT03433339

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active transcutaneous spinal direct current stimulation
Description: Active anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcutaneous spinal direct current stimulation
Description: Sham anode electrodes placed at Thoracic 10 level, Cathode electrode placed on right shoulder.
Study: NCT00837369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: 400ug IV bolus injection, single dosage
Study: NCT02790931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
Study: NCT03789214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo Sleep Medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Dose Suvorexant
Description: Low Dose Suvorexant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Dose Suvorexant
Description: High Dose Suvorexant
Study: NCT00479193

Intervention type: DRUG
Group type: OTHER
Intervention: bacitracin/xeroform
Description: single layer, change every 3 days

Intervention type: DRUG
Group type: OTHER
Intervention: Polymem
Description: single layer of Polymen, change every 3 days
Study: NCT01232595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LFF571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin (POC)
Study: NCT01708161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: BYL719 is a small molecule inhibiting PI3-Kinase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 479
Description: AMG 479 is a monoclonal antibody directed against IGF1-R.
Study: NCT04289142

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride Group
Description: Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.
Study: NCT02581787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresolimumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SABR
Study: NCT00765557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MiraLAX
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MiraLAX
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Every subject will be given one bottle of the polyethylene glycol/placebo, divided into daily doses and depending on the patient's age, will be instructed to take 8.5 grams or 17 grams of the medication dispensed in daily dose vials to be mixed with water or juice. They will take the medication once a day for one month.
Study: NCT01642979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamisole+cyclosporin A+Glucocorticoids
Description: Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclosporin A+Glucocorticoids
Description: cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Glucocorticoids 0.5-1mg/kg every day(prednisone)
Study: NCT01191918

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil and Lithium
Description: Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus Lithium
Study: NCT01655797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy for insomnia
Description: Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
Study: NCT04188587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177 Lu-PSMA-I&T
Description: All patients were intravenous injected with single dose 2.0-8.0 GBq. The time of the next treatment cycle is determined according to the patient's condition, and it is recommended to treat once every 8-12 weeks.
Study: NCT01058655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Study: NCT02154074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia induction
Description: general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anesthesia induction
Description: general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia induction
Description: general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: general anesthesia induction
Description: general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: inhale Isoflurane 1.5MAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: inhale Isoflurane 1.5MAC
Study: NCT04856436

Intervention type: DRUG
Intervention: Benzodiazepine
Description: Exposure to benzodiazepine during early pregnancy
Study: NCT02154074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoflurane
Description: inhale Isoflurane 1.5MAC
Study: NCT02154074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: inhale Isoflurane 1.5MAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: the same volume of saline + Isoflurane during operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: the same volume of saline + Isoflurane during operation
Study: NCT02544646

Intervention type: OTHER
Group type: OTHER
Intervention: Changes in Ocular rigidity
Description: measured before the operation and 28±7 days after the operation
Study: NCT03917238

Intervention type: RADIATION
Group type: OTHER
Intervention: gallium-68-exendin injection followed by PET/CT scan
Description: After injecting gallium-68-exendin, a PET/CT scan is performed during the honeymoon phase and repeated once the honeymoon phase has ended
Study: NCT02733094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Study: NCT04185779

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: Diagnostic colonoscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy
Description: Diagnostic colonoscopy
Study: NCT04110145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Linaclotide, capsules, mixed with water and administered orally, once daily in fasted state.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, capsules, mixed with water and administered orally, once daily in fasted state
Study: NCT03195764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-1101 (Tosylate)
Description: T-1101 (Tosylate) powder in bottle
Study: NCT01827956

Intervention type: OTHER
Intervention: Blood sample for identifying the polymorphism
Description: Blood sample for identifying the polymorphism
Study: NCT04342377

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Selective Targeted Sampling
Description: Mediastinal lymph nodes are assessed with the CLNS, and only those appearing malignant with the score are biopsied. Triple Normal lymph nodes (normal appearing on PET, CT and EBUS) are not biopsied.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Sampling
Description: All examined mediastinal lymph nodes are biopsied, regardless of whether they appear normal during PET, CT and EBUS.
Study: NCT01258348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: LY573636-sodium
Description: Participant specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on Day 4 of a 42-day (6-week) cycle.~Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of participants enrolled after MTD will receive albumin-tailored doses.~Participants may continue on treatment until clinical or objective disease progression.
Study: NCT02741050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity Intervention
Description: The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
Study: NCT02839291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life questionaries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous or oral bone antiresorptive treatments
Study: NCT04214990

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin 100mg
Description: Daily aspirin 100 mg for 5 years

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Daily placebo for 5 years
Study: NCT01258348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 37.5 or 50 milligrams (mg), administered orally, daily for a 42-day (6-week) cycle.~Participants may continue on treatment until clinical or objective disease progression.
Study: NCT02144532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: short-sleeved vest CICATREX SED®)
Description: Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
Study: NCT00444223

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fluorine F 18 FEQA + positron emission tomography
Study: NCT01412645

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Resveratrol
Description: 500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or~1 placebo 2 times daily for 4 months